बोर्टेज़ोमिब और डेक्सामेथासोन का इंटरैक्शन

Strong CYP3A4 Inducers: Avoid concomitant use.

Avoid coadministration with strong CYP3A4 inducers.

In the bortezomib vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with ≥ Grade 2 peripheral neuropathy following dose adjustment or interruption.

The incidence of bleeding (≥ Grade 3) was 2% on the bortezomib arm and was < 1% in the dexamethasone arm.

Effects of Other Drugs on BORUZU Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [see Clinical Pharmacology (12.3) ] which may decrease bortezomib efficacy.